Citadel Advisors
DCOY icon

Citadel Advisors’s Decoy Therapeutics DCOY Stock Holding History

Citadel Advisors’s Portfolio DCOY Stock Details DCOY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-17
Closed -$15.7K – 15368
2023
Q4 		$15.7K Buy
+17
New +$17K ﹤0.01% 12828
2022
Q3 		– Sell
-5
Closed -$35K – 13529
2022
Q2 		$35K Buy
+5
New +$43.1K ﹤0.01% 12144
2021
Q3 		– Sell
-2
Closed -$91K – 14576
2021
Q2 		$91K Buy
+2
New +$89K ﹤0.01% 12989
2021
Q1 		– Hold
0
– – – 13070
2019
Q1 		– Hold
0
– -$20K – 9822
2018
Q4 		– Hold
0
– – – 8758
2016
Q3 		– Hold
0
– -$104K – 7727
2016
Q2 		– Hold
0
– – – 6176
2016
Q1 		– Hold
0
– -$59K – 7851
2015
Q4 		– Hold
0
– – – 7172

Other funds holding DCOY

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
HKAM
Horizon Kinetics Asset Management New York $8.82B AUM 23.05% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citadel Advisors's DCOY Position: Q1 2024 in Review

Citadel Advisors sold out of Decoy Therapeutics (DCOY) in Q1 2024, closing a stake of 17 shares — an estimated $15.7K sold.

Citadel Advisors first reported a position in DCOY in Q2 2021 and held it in 3 quarters. The position peaked at $91K in Q2 2021. 7 funds tracked by Wall St. Rank hold DCOY as of Q1 2024.

  • Citadel Advisors reported no remaining Decoy Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Citadel Advisors sold 17 Decoy Therapeutics shares in Q1 2024, an estimated $15.7K.
  • Citadel Advisors first reported a position in Decoy Therapeutics in Q2 2021 and held it in 3 quarters.
  • Citadel Advisors's Decoy Therapeutics position peaked at $91K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Decoy Therapeutics as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.